HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells

Purinostat Mesylate (PM) is a novel highly selective and active HDAC I/IIb inhibitor, and the injectable formulation of PM (PMF) based on the compound prescription containing cyclodextrin completely can overcome PM's poor solubility and improves its stability and pharmacokinetic properties. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Qiang, yang, Linyu, Feng, Yunyu, Zhu, Zejiang, Li, Ning, Zheng, Li, Sun, Yuanyuan, Pan, Cong, Qiu, Huandi, Cui, Xue, He, Wei, Wang, Fang, Yi, Yuyao, Tang, Minghai, Yang, Zhuang, Yang, Yunfan, Li, Zhihui, Chen, Lijuan, Hu, Yiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486186/
https://www.ncbi.nlm.nih.gov/pubmed/36185739
http://dx.doi.org/10.1016/j.bioactmat.2022.08.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486186/
https://www.ncbi.nlm.nih.gov/pubmed/36185739
http://dx.doi.org/10.1016/j.bioactmat.2022.08.006

Ejemplares similares